Business Context and Reporting Period
Kiora Pharmaceuticals, Inc. (KPRX) filed a Form 8-K on March 24, 2023, reporting a change in its independent registered public accounting firm. The company is incorporated in Delaware and trades on the NASDAQ.
Financial Metrics
This filing does not contain specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document references the prior fiscal years ended December 31, 2022, and 2021, noting that the outgoing auditor's report included an explanatory paragraph regarding the company's ability to continue as a going concern.
Material Changes
- Dismissal of Auditor: The Audit Committee dismissed EisnerAmper LLP as the independent registered public accounting firm effective March 24, 2023. EisnerAmper had served the company since 2014.
- Appointment of New Auditor: Haskell & White LLP was appointed as the new independent registered public accounting firm, effective March 24, 2023, for the fiscal year ending December 31, 2023, and related interim periods.
- Audit Opinion Status: The outgoing auditor's report for 2021 and 2022 did not contain an adverse opinion, disclaimer, or qualification, aside from the going concern explanatory paragraph.
- Disagreements: There were no disagreements with the outgoing auditor on accounting principles or auditing scope. However, the auditor concurred with the company's assessment of a material weakness in internal controls over financial reporting.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking guidance, management commentary on operations, or specific risk factors beyond the noted material weakness in internal controls and the going concern qualification in the prior audit report. No consultations regarding accounting principles or audit opinions were made with the new auditor prior to their appointment.
Key Facts for Investor Verification
- Verify the specific nature of the material weakness in internal controls over financial reporting referenced in the prior audit.
- Review the most recent 10-K or 10-Q filings to assess the current status of the "going concern" qualification mentioned in the 2022 audit report.
- Confirm the transition timeline and any potential delays in the audit of the 2023 fiscal year due to the change in auditors.
- Check for any subsequent filings regarding the resolution of the internal control material weakness.